Prof. Ken Anderson on opportunities in myeloma research and his lifetime achievement award
Day 1 Highlights from the chair of BOPA 2017
A free market and data-driven approach to solve the issue of drug cost
Can biosimilars ensure access to drugs for everyone?
ECHELON-1 trial data from ASH 2017: controversies and clinical translation